Issue 108

PTSD and payers in psychedelic healthcare

Veteran affairs receive bipartisan support across North America, with public opinion prompting lawmakers and regulators to support innovations in veteran healthcare.

The FDA designated MAPS’ MDMA-assisted therapy for post-traumatic stress disorder (PTSD) a breakthrough therapy in 2017 with regulatory approval expected in 2024.

Earlier this month, Apex Labs received approval for its Phase IIb trial with psilocybin in the treatment of PTSD – with patients taking the psychedelic medicine at home with minimal psychiatric intervention.

This is the first study of its kind in North America and, if successful, could transform how psychedelic medicines are delivered. PSYCH spoke with the company’s CEO Tyler Powell on the announcement.

REGULATING PSILOCYBIN SERVICES

Following the widespread legalisation of cannabis, lawmakers are now turning their attention to psychedelic medicines.

THE UK'S MENTAL HEALTH CRISIS

According to the NHS, last year 8.3 million patients received at least one prescription for antidepressants.

BUSINESS AND INVESTMENT

Clearmind raises US$7.5m and uplists to NASDAQ.

MAPS completes second Phase III study.

The psychedelic healthcare industry gains momentum.

Mindset Pharma and PharmAla enter distribution agreement.

Filament to supply Centre for Addiction and Mental Health with psilocybin.

Psychedelic-assisted therapy for mental health conditions.

Following the success of the SOLD OUT PSYCH Symposium in 2022, the industry-leading conference returns to the iconic British Museum on Thursday, 6 July 2023.

Super Early Bird tickets now on sale for £250 + VAT.

TICKET REGISTRATION